Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1265162 in Healthy Male Volunteers in a Partially Randomised, Single Blind, Placebo-controlled Trial
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs BI 1265162 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Mar 2018 Status changed from recruiting to completed.
- 30 Nov 2017 New trial record
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.